Document Report Card

Basic Information

ID: ALA2034889

Journal: Bioorg Med Chem Lett

Title: The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity.

Authors: Cumming JG, Bower JF, Waterson D, Faull A, Poyser PJ, Turner P, McDermott B, Campbell AD, Hudson J, James M, Winter J, Wood C.

Abstract: A novel N-aryl piperazine-1-carboxamide series of human CCR2 chemokine receptor antagonists was discovered. Early analogues were potent at CCR2 but also inhibited the hERG cardiac ion channel. Structural modifications which decreased lipophilicity and basicity resulted in the identification of a sub-series with an improved margin over hERG. The pharmacological and pharmacokinetic properties of the lead compound from this series, N-(3,4-dichlorophenyl)-4-[(2R)-4-isopropylpiperazine-2-carbonyl]piperazine-1-carboxamide, are described.

CiteXplore: 22608963

DOI: 10.1016/j.bmcl.2012.04.118